Fortis Group Advisors LLC Grows Stake in Novo Nordisk A/S $NVO

Key Points

• Fortis Group Advisors LLC boosted its stake in Novo Nordisk by 504.9% in the fourth quarter, ending with 75,204 shares valued at about $3.83 million.
• Novo Nordisk shares were up 1.8% to $45.07, while the company remains well below its 52-week high of $81.44 and trades at a market cap of $201.23 billion.
• Analysts remain cautious overall: Novo Nordisk has a consensus “Hold” rating with an average target price of $65.56, as competition in the obesity-pill market and mixed analyst actions weigh on sentiment.

Fortis Group Advisors LLC increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 504.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,204 shares of the company's stock after acquiring an additional 62,771 shares during the period. Fortis Group Advisors LLC's holdings in Novo Nordisk A/S were worth $3,826,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S in the third quarter worth about $25,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust purchased a new position in Novo Nordisk A/S in the fourth quarter worth about $28,000. Maseco LLP purchased a new position in Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S in the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 1.8%

Shares of NYSE:NVO opened at $45.07 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The business has a 50 day simple moving average of $40.05 and a two-hundred day simple moving average of $46.51. The firm has a market capitalization of $201.23 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. On average, equities analysts predict that Novo Nordisk A/S will post 3.47 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on NVO shares. Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research report on Thursday, February 12th. Wolfe Research started coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a "peer perform" rating for the company. BMO Capital Markets reiterated a "market perform" rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. Finally, JPMorgan Chase & Co. restated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
• Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk CPSE: NOVO B Has Changed Its Investment Story
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
• Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
• Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential
• Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook (NVO)
• Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.